A Comprehensive Study of the Immunophenotype and its Clinicopathologic Significance in Adult T-Cell Leukemia/Lymphoma

Tamaki, Tomoko; Karube, Kennosuke; Sakihama, Shugo; Tsuruta, Yuma; Awazawa, Ryoko; Nakada, Norihiro; Matsumoto, Hirofumi; Yagi, Noriyuki; Ohshiro, Kazuiku; Nakazato, Iwao; Kitamura, Sakiko; Nishi, Yusuke; Miyagi, Takuya; Yamaguchi, Sayaka; Nakachi, Sawako; Masuzaki, Hiroaki; Takahashi, Keiichi; Fukushima, Takuya; Wada, Naoki

doi:10.1016/j.modpat.2023.100169

Cited by 7 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with our findings, a previous study reported no difference in eosinophil infiltration between AITL and PTCL unspecified (currently known as PTCL, NOS) 14 . These histological features were generally the same as those of the previously reported study 13 …”

Section: Discussionmentioning

confidence: 99%

“…14 These histological features were generally the same as those of the previously reported study. 13 Regarding FOXP3, the normal counterpart cell of ATLL is considered to be CD4 + CD25 + FOXP3 + T regulatory cells (Treg), and these cells are of a different lineage from TFH cells. While FOXP3 is considered a key molecule in Treg cells, 15 previous studies have reported that ATLL do not always express FOXP3.…”

Section: Discussionmentioning

confidence: 99%

“…The diagnostic clue for ATLL is confirming the positivity of serum HTLV‐1 antibody 1,7,11,12 . Recently, it has been reported that some ATLL cases are positive for TFH markers, but no study has examined their comprehensive clinical characteristics 13 . In this study, in addition to the pathological analysis of ATLL with TFHP, clinical characteristics and prognosis were also examined.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinicopathological features of adult T‐cell leukemia/lymphoma with T‐follicular helper phenotype

Muto,

Miyoshi,

Nakashima

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

AimsT‐follicular helper (TFH) cells are effector T‐cells that are crucial for B‐cell selection and differentiation. T‐cell lymphomas derived from TFH cells have distinct characteristics. Additionally, in the World Health Organization (WHO) classification 5th edition, three lymphomas were introduced as independent disease entities with TFH cell origin. We aimed to investigate the clinicopathological features of adult T‐cell leukemia/lymphoma (ATLL) with a TFH phenotype (TFHP).Methods and ResultsWe performed TFH immunohistochemistry analysis of five biomarkers for the biopsy specimen, with TFHP being indicated by a positive result for more than two markers. Among 75 cases of ATLL, 37.3% of them showed TFHP. Compared with cases of ATLL without TFHP, cases of ATLL with TFHP showed higher C‐reactive protein levels (p = 0.0219) and increased high endothelial venule proliferation (p = 0.024). However, there were no significant between‐group differences in overall survival as well as other clinical and morphological findings. Furthermore, there was no significant between‐group difference in TFH markers and FOXP3 expression.ConclusionSome patients with ATLL may present a TFHP, which should not preclude the diagnosis of ATLL. Although presenting a TFHP does not affect prognosis, it is important to identify cases of ATLL with a TFHP since it may inform future treatment strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathological features of adult T‐cell leukemia/lymphoma with T‐follicular helper phenotype

Muto,

Miyoshi,

Nakashima

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…In this case, it is generally a CD4+ CD8-T lymphocyte phenotype, although to a lesser extent, they can be double-positive (CD4+ CD8+) or CD4− CD8+. Furthermore, the expression of CD25 and CCR4 is typical, the latter being essential, as it is currently a therapeutic target [38]. More rarely, eosinophilia is found to be associated with other T lymphomas, although histologically, it is frequently found with a peritumoral arrangement [32].…”

Section: Mature T-cell Neoplasmsmentioning

confidence: 99%

Hematological Neoplasms with Eosinophilia

Morales-Camacho,

Caballero-Velázquez,

Borrero

et al. 2024

Cancers

View full text Add to dashboard Cite

Eosinophils in peripheral blood account for 0.3–5% of leukocytes, which is equivalent to 0.05–0.5 × 109/L. A count above 0.5 × 109/L is considered to indicate eosinophilia, while a count equal to or above 1.5 × 109/L is defined as hypereosinophilia. In bone marrow aspirate, eosinophilia is considered when eosinophils make up more than 6% of the total nuclear cells. In daily clinical practice, the most common causes of reactive eosinophilia are non-hematologic, whether they are non-neoplastic (allergic diseases, drugs, infections, or immunological diseases) or neoplastic (solid tumors). Eosinophilia that is associated with a hematological malignancy may be reactive or secondary to the production of eosinophilopoietic cytokines, and this is mainly seen in lymphoid neoplasms (Hodgkin lymphoma, mature T-cell neoplasms, lymphocytic variant of hypereosinophilic syndrome, and B-acute lymphoblastic leukemia/lymphoma). Eosinophilia that is associated with a hematological malignancy may also be neoplastic or primary, derived from the malignant clone, usually in myeloid neoplasms or with its origin in stem cells (myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions, acute myeloid leukemia with core binding factor translocations, mastocytosis, myeloproliferative neoplasms, myelodysplastic/myeloproliferative neoplasms, and myelodysplastic neoplasms). There are no concrete data in standardized cytological and cytometric procedures that could predict whether eosinophilia is reactive or clonal. The verification is usually indirect, based on the categorization of the accompanying hematologic malignancy. This review focuses on the broad differential diagnosis of hematological malignancies with eosinophilia.

show abstract

ETS1 Function in Leukemia and Lymphoma

Luchtel

2024

Transcription Factors in Blood Cell Development

View full text Add to dashboard Cite

A Comprehensive Study of the Immunophenotype and its Clinicopathologic Significance in Adult T-Cell Leukemia/Lymphoma

Cited by 7 publications

References 25 publications

Clinicopathological features of adult T‐cell leukemia/lymphoma with T‐follicular helper phenotype

Clinicopathological features of adult T‐cell leukemia/lymphoma with T‐follicular helper phenotype

Hematological Neoplasms with Eosinophilia

ETS1 Function in Leukemia and Lymphoma

Contact Info

Product

Resources

About